EP2997031A1 - Procédé pour la préparation de pemetrexed disodique amorphe de haute pureté et formes cristallines de l'acide n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-l-glutamique - Google Patents

Procédé pour la préparation de pemetrexed disodique amorphe de haute pureté et formes cristallines de l'acide n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-l-glutamique

Info

Publication number
EP2997031A1
EP2997031A1 EP14732453.7A EP14732453A EP2997031A1 EP 2997031 A1 EP2997031 A1 EP 2997031A1 EP 14732453 A EP14732453 A EP 14732453A EP 2997031 A1 EP2997031 A1 EP 2997031A1
Authority
EP
European Patent Office
Prior art keywords
pyrrolo
dihydro
oxo
pyrimidin
benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14732453.7A
Other languages
German (de)
English (en)
Inventor
Olga Michalak
Kamil JATCZAK
Wieslaw Pucko
Anna WITKOWSKA
Marta Laszcz
Iwona BUJAK
Aleksandra GROMAN
Marcin Cybulski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instytut Farmaceutiyczny
Original Assignee
Instytut Farmaceutiyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL403942A external-priority patent/PL403942A1/pl
Priority claimed from PL408089A external-priority patent/PL408089A1/pl
Application filed by Instytut Farmaceutiyczny filed Critical Instytut Farmaceutiyczny
Publication of EP2997031A1 publication Critical patent/EP2997031A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to a process for the preparation of high purity amorphous pemetrexed disodium as well as to the crystalline forms of N-[4-[2-(2- amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, which are used in the preparation thereof.
  • the present invention also discloses the methods of preparation of the new crystalline forms of N-[4-[2-(2-amino-4,7-dihydro-4- oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid.
  • the amorphous pemetrexed disodium can be used as the active ingredient of the pharmaceutical product in a form of lyophilized powder.
  • Pemetrexed is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. It works by inhibiting three enzymes used in purine and pyrimidine synthesis de novo - thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARPT). By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.
  • TS de novo - thymidylate synthase
  • DHFR dihydrofolate reductase
  • GARPT glycinamide ribonucleotide formyltransferase
  • the pharmaceutical product containing pemetrexed disodium as the active ingredient, indicated for the potential treatment of locally advanced or metastatic non- small cell lung cancer and mesothelioma, is available on the market under brand name ALIMTA®,. It is a sterile lyophilized powder for intravenous infusion. The lyophilizate is to be reconstituted in a sterile physiological salt and further dilution prior to infusion.
  • ALIMTA® except of pemetrexed disodium equivalent to 100 mg or 500 mg pemetrexed, contains mannitol and optionally hydrochloric acid and/or sodium hydroxide to adjust pH.
  • L-glutamic acid derivatives sodium salts have been obtained as the intermediates in the synthesis of the corresponding free acids, isolated in the crystalline form after the basic hydrolysis of appropriate diester followed by neutralization with hydrochloric acid, and then re- crystallized.
  • a number of pemetrexed disodium crystalline forms and the methods for preparation thereof have been disclosed in the prior art but particular attention has been paid to syntheses of amorphous pemetrexed, because it has been proved to be very convenient in the preparation of the lyophilized pharmaceutical products.
  • the amorphous pemetrexed disodium disclosed in WO 2008/124485 was obtained by removing the solvent from the solution of pemetrexed disodium in water, DMSO, alcohol, ketone, or the mixtures thereof, by the commonly used laboratory techniques, such as evaporation, distillation under vacuum or atmospheric pressure, or spry drying.
  • the amorphous pemetrexed disodium has been characterized by a mass loss upon drying at the level of about 8.268%, as determined by a thermogravimetric analysis method.
  • WO 2010/028105 methods for preparation of the amorphous pemetrexed disodium have been revealed, comprising first dissolving pemetrexed salt in a solvent, and then precipitating the product by adding an anti-solvent or by heating the solution in alcohol.
  • EP 1943252 Bl specification process for preparation of the lyophilized pemetrexed disodium as a pure substance or in a composition with a carrier, directly from diacid or its addition salts without isolation of disodium salt, has been reported.
  • pemetrexed diacid or its mono- or di-base-addition salts were contacted with sodium cations generating compound, such as sodium hydroxide, carbonate, phosphate or sulfate in an organic solvent, comprising water or the mixture of water and tert-butanol, dimethyl sulfoxide or 1,4-dioxane.
  • sodium cations generating compound such as sodium hydroxide, carbonate, phosphate or sulfate in an organic solvent, comprising water or the mixture of water and tert-butanol, dimethyl sulfoxide or 1,4-dioxane.
  • the lyophilizate was obtained by removing the solvent in the drying or freeze-drying processes.
  • pemetrexed disodium can be obtained, in general, in the reaction of pemetrexed free diacid or the acid addition salt of its ester, such as p-toluenesulfonic acid addition salt, with stoichiometric amount or molar excess of sodium source compound, such as sodium hydroxide, carbonate, phosphate or sulfate in aqueous media or in a water miscible solvent.
  • sodium source compound such as sodium hydroxide, carbonate, phosphate or sulfate in aqueous media or in a water miscible solvent.
  • an addition of the precipitation initiating solvent is necessary.
  • obtaining the amorphous pemetrexed disodium product complying with the requirements regarding pharmaceutical purity as well as amorphous homogeneity (i.e.
  • pemetrexed diacid crystalline forms A, B, C, D, E, F, and G have been dislosed.
  • Pemetrexed diacid forms A and B crystallize as hydrates, containing 7.7% and 2.5 - 3.9% of water, respectively, by adjusting pH to 3.0 - 4.5 of the solution of pemetrexed disodium in water or in the mixture of water and the water miscible organic solvent.
  • Pemetrexed diacid crystalline forms C, D and E are obtained as solvates with DMSO or DMF, when precipitating from the mixtures of DMSO/water/methanol, DMF/water/methanol, or DMF/ethanol.
  • Pemetrexed diacid crystalline form F is obtained from the salt of pemetrexed diethyl ester with p-toluenesulfonic acid, which is subjected to basic hydrolysis, and adjusting pH of the solution to about 3.9 - 4.1.
  • Anhydrous pemetrexed diacid crystalline form G is formed upon drying form B at the temperature of about 160°C - 200°C.
  • Crystalline form H was obtained, when pH of the solution, containing disodium salt in the mixture of water and water miscible solvent, was brought to about 1.5 - 2.5.
  • the group of the water miscible solvents comprised alcohols, preferably ethanol, acetonitrile, THF, dimethyl ethylene glycol and acetone.
  • Pemetrexed diacid crystallized as form I from the aqueous solution of pemetrexed salt at the concentration below 0.07 mol/L when adjusting pH of the solution to about 2.0 - 3.0, while crystalline form J was obtained from the aqueous solution of pemetrexed salt at the concentration higher than 0.07 mol/L when pH of the solution was brought to about 2.0 - 4.0.
  • All the said obstacles have been circumvented in the process according to the present invention, due to: a) changing the proportion of the reagents used in the process of pemetrexed disodium formation, b) using pemetrexed diacid of a well defined crystalline form and strictly established chemical composition, c) removing the residual solvents by final maceration of the amorphous pemetrexed disodium in an alkane type aprotic solvent and subsequent drying the amorphous solid.
  • One aspect of the present invention is the process for preparation of high purity amorphous pemetrexed disodium in the reaction of N-[4-[2-(2-amino-4,7-dihydro-4- oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)etyhl]benzoyl]-L-glutamic acid with sodium cations generating compound, characterized by the use of the molar shortage of sodium cations generating compound in respect to carboxyl groups of N-[4-[2-(2-amino-4,7- dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic free acid, under anhydrous conditions.
  • 2% molar shortage of sodium cations generating compound to one carboxyl group of N-[4-[2-(2-amino-4,7 ⁇ dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid is used.
  • the other aspect of the invention is the crystalline Form 2 of N-[4-[2-(2-amino-
  • Another aspect of the invention is the use of the crystalline form of N-[4-[2-(2- amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, selected from Form 1 and Form 2, to produce the amorphous pemetrexed disodium of purity above 99.7%.
  • Fig. 1 represents X-ray powder diffraction pattern (XRPD) of the crystalline Form 1 of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]- L-glutamic acid.
  • XRPD X-ray powder diffraction pattern
  • Fig. 2 represents DSC profile of the crystalline Form 1 of N-[4-[2-(2-amino-4,7- dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, obtained by differential scanning calorimetry.
  • Fig. 3 represents the thermal characteristics of the crystalline Form 1 of N-[4-[2-(2- amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, obtained by the thermogravimetric analysis (TGA).
  • Fig. 4. represents DSC the profile of the crystalline Form 1 of N-[4-[2-(2-amino-4,7- dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, obtained by the differential scanning calorimetry with heating-cooling loop.
  • Fig. 5 represents X-ray powder diffraction pattern (XRPD) of the crystalline Form 2 of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]- L-glutamic acid.
  • XRPD X-ray powder diffraction pattern
  • Fig. 6 represents DSC profile of the crystalline Form 2 of N-[4-[2-(2-amino-4,7- dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, obtained by the differential scanning calorimetry.
  • Fig. 7 represents the thermal characteristics of the crystalline Form 2 of N-[4-[2-(2- amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, obtained by the thermogravimetric analysis (TGA).
  • TGA thermogravimetric analysis
  • Fig. 8 represents X-ray powder diffraction pattern (XRPD) of the amorphous pemetrexed disodium.
  • Fig. 9 represents DSC curve of the amorphous pemetrexed disodium, obtained by the differential scanning calorimetry.
  • Fig. 10 represents the thermal characteristics of the amorphous pemetrexed disodium.
  • the strategy disclosed in the present invention is based on the observation, that when the molar shortage of sodium methanolate to diacid in synthesis of pemetrexed disodium is used, the main impurity detected by HPLC analysis at 1.03 RRT is not formed, whereas the use of even small (eg. 10%) molar excess of sodium methanolate to diacid, results in the formation of substantial amounts, reaching 0.27-0.30%, of this impurity (the comparative example 3).
  • [4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L- glutamic acid with the sodium cations generating compound embraces: a ) reacting N- [4- [2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3 -d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid with the molar shortage of sodium cations generating compound to carboxyl groups of N-[4-[2-(2-ammo-4,7-dihydro-4-oxo-3H-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid under anhydrous conditions, b) optionally, adding anti-solvent to precipitate the product of the
  • high purity amorphous pemetrexed disodium refers to the substance free of other polymorphic and pseudo-polymorphic forms at amounts detectable by routinely used analytical methods, such as X-ray powder diffraction and infra-red absorption, that means containing below 2%, preferably below 1% of other crystalline forms.
  • high purity amorphous pemetrexed disodium is to be characterized by chemical purity above 99.7%, determined by high performance liquid chromatography (HPLC).
  • the starting N-[4-[2-(2-amino-4,7-dihydro-4- oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid herein referred to as pemetrexed diacid
  • pemetrexed diacid can be obtained following the synthetic pathway disclosed, among the others, in EP 589720 A2 and EP 1212325 Al, as depicted in Scheme 1.
  • This process is based on coupling 4-[2-(2-amino-4-oxo-3,7-dihydro-3H-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoic acid, activated by 4-chloro-2,4-dimethoxy-l,3,5-triazine (CDMT), with ethyl L-glutamate hydrochloride in the presence of N-methylmorpholine, then purifying the product as an acid addition salt with p-toluenesulfonic acid.
  • CDMT 4-chloro-2,4-dimethoxy-l,3,5-triazine
  • pemetrexed diethyl ester p-toluenesulfonate is subjected to hydrolysis upon sodium hydroxide aqueous solution at ambient temperature for 2 h, yielding the expected reaction product.
  • alcohol solvent such as ethanol
  • pH of the post-reaction mixture is adjusted to about 3.0 - 3.5, then the solution is heated at 70°C, and after cooling down to ambient temperature the solid pemetrexed diacid precipitates.
  • the amorphous pemetrexed disodium of expected pharmaceutical purity can be obtained when the pemetrexed diacid of chemical purity above 99% is used.
  • pemetrexed diacid The purity of pemetrexed diacid is crucial for the preparation of the amorphous pemetrexed disodium of demanded purity, therefore pemetrexed diacid usually requires the additional crystallization(s) to increase its purity prior its use in the following steps of synthesis.
  • Pemetrexed diacid can be easily re-crystallized, dissolving the solid in aprotic solvent, such as dimethyl sulfoxide (DMSO), dimethyloformamide (DMF) or N- methylpyrrolidon, and then precipitating the solid by the addition of a polar anti-solvent selected form the group of alcohol solvents, preferably ethanol (EtOH).
  • aprotic solvent such as dimethyl sulfoxide (DMSO), dimethyloformamide (DMF) or N- methylpyrrolidon
  • a polar anti-solvent selected form the group of alcohol solvents, preferably ethanol (EtOH).
  • Pemetrexed diacid can be isolated as any optional crystalline form.
  • pemetrexed diacid is subjected to one or more crystallizations, preferably two crystallizations, in the mixture of DMSO/EtOH.
  • Crystalline Form 1 is obtained, when to pemetrexed diacid dissolved in dimethyl sulfoxide ethanol is added as the anti-solvent, and EtOH/DMSO volume ratio is maintained from about 2.0 to 4.0. Anti-solvent is added to that solution dropwise or one- time at the temperature range of 40 - 55°C, furnishing crystalline product precipitation. After bringing down the temperature of the reaction mixture to ambient, the crystalline solid is filtered off, washed with ethanol, and air dried in an air flow drier at 40-45 °C to the constant mass. According to the same manner the second crystallization is performed in DMSO/EtOH, yielding pemetrexed diacid of chemical purity above 99.7% (HPLC). The formation of the crystalline Form 1 also takes place after water addition to the reaction mixture at the amount not higher than 10% of the total volume of other solvents used (DMSO and EtOH).
  • Crystalline Form 2 is obtained analogously, when to pemetrexed diacid dissolved in dimethyl sulfoxide, ethanol is added as anti-solvent at higher EtOH/DMSO volume ratio, from about 4.2 do 6.0.
  • Crystalline Form 1 is thermodynamically more stable than form 2.
  • XRPD X-ray powder diffraction pattern
  • the data are collected in Table 1 :
  • FIG. 1 An exemplary X-ray powder diffraction pattern of pemetrexed diacid crystalline Form 1 is presented in Fig. 1.
  • DSC profile of pemetrexed diacid crystalline Form 1 obtained by the differential scanning calorimetry, depicted in Fig. 2, is characterized by a broad endothermic effect, which comes from residual solvents evaporation, at the temperature range from about 30 to 120°C.
  • the jagged base line, which appears after melting effect, is the result of decomposition of the compound. It is assumed, within this temperature range evaporation of adsorbed DMSO (boiling point 189°C) takes place.
  • XRPD X-ray powder diffraction pattern
  • Table 2 The data are collected in Table 2:
  • the jagged base line shown after the melting effect represents substance decomposition. Supposedly, at this temperature range evaporation of adsorbed DMSO (boiling point 189°C) also takes place.
  • the new pemetrexed diacid crystalline forms 1 and 2 due to their well defined chemical structure and DMSO content, which varies from 27 to 31%, are very useful substrates for the preparation of high purity pemetrexed disodium.
  • the content of DMSO molecules in the crystalline form should be considered, while calculating exact amount of sodium generating compound, for example sodium methanolate, in particular when molar shortage of this reagent in regard to pemetrexed diacid is used.
  • the exact content of pemetrexed free diacid in its crystalline forms 1 or 2 obtained according to the present invention can be determined by potentiometric alkacymetric titration of carboxyl groups or titration of the primary amine groups with perchloric acid.
  • the potentiometric titration and gas chromatography analysis (GC) are useful tools to determine the content of DMSO; both analytical methods provide consistent results of the pemetrexed diacid content determination.
  • the synthesis of the amorphous pemetrexed disodium is performed according to the following manner.
  • Preparation of the amorphous pemetrexed disodium is accomplished in the reaction of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid with the sodium cations generating compound, under anhydrous conditions.
  • the sodium cations generating compound is used at the amount below the molar ratio in regard to carboxyl groups of reacting N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid.
  • the sodium cations generating compound is used at 2% molar shortage in regard to one carboxyl group of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H- pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid.
  • the sodium cations generating compound is selected from the group comprising sodium hydroxide, carbonate or alkoxide, preferably sodium alkoxide, more preferably sodium methoxide.
  • the anhydrous reaction conditions are maintained due to the use of alcohol solvent, such as methanol, ethanol or isopropanol.
  • the yield of the amorphous pemetrexed disodium isolated from the post-reaction mixture can be increased by adding the anti-solvent to the reaction mixture.
  • the anti-solvent is selected from the group of alcohol solvents comprising ethanol, isopropanol, n-butanol, terf-butanol; acetonitrile; acetone; ethers, including, diisopropyl ether, tert-b tyl methyl ether, dioxane, tetrahydrofurane; chloroalkanes, such as chloroform or methylene dichloride.
  • alcohol solvents especially ethanol, isopropanol or n-butanol, are used.
  • reaction mixture is stirred at ambient temperature until the product starts precipitating.
  • the amorphous pemetrexed disodium is isolated by the standard procedures, for example, filtrating, decanting or solvent evaporating, and then washed with the proper solvent, preferably, the alcohol.
  • the amorphous pemetrexed disodium can be purified, preferably, by maceration, i.e. stirring the suspension in a small amount of the solvent.
  • the volume-weight ratio of the solvent mixture in respect to the mass of the crude pemetrexed disodium used in maceration ranges from 2: 1 to 10: 1, preferably, it is about 3:1 (v/w), thus it is significantly smaller in comparison with the solvents ratio used in the standard crystallization.
  • the crude amorphous solid of pemetrexed disodium is suspended in the alcohol, preferably, in methanol or ethanol, upon stirring. Stirring is continued at ambient temperature for 1 to 24 h, preferably for 3 h.
  • the solid amorphous pemetrexed disodium, separated and dried, is subjected to the second maceration in the aprotic solvent, preferably selected from the group comprising the alkanes, such as pentane, heptane, hexane, or cyclohexane. Stirring the suspension is continued for 1 to 24 h, preferably for 3 h.
  • the term 'ambient temperature' refers to the temperature within the range from
  • XRPD X-ray powder diffraction pattern
  • TGA curve of the amorphous pemetrexed disodium obtained under the dynamic heating regime ranging from 30°C to 300°C at the heating rate 10°C/min, the mass loss at the temperature range of about 30°C-220°C is observed.
  • the comparative analysis of TGA and SDTA curves indicates that this effect corresponds to the solvents evaporation.
  • the loss of mass accounting for 7.40% is slightly higher than 6.18% water content measured by coulometric titration. This difference can be attributed to the presence of other solvents, which were used in the synthetic process.
  • the DSC profile of the amorphous pemetrexed disodium obtained by the differential scanning calorimetry at the dynamic heating from 25 to 300°C at the heating rate 10°C/min, depicted in Fig. 10, is characterized by two endothermic and one exothermic peak.
  • the first broad endothermic peak which appears at the temperature range of 30-200°C results from the evaporation of adsorbed solvents.
  • the second endothermic peak at about 234°C is the effect of substance melting, and the exothermic peak at about 251 °C represents substance decomposition.
  • the present invention provides the process with the use of pemetrexed diacid crystalline forms 1 or 2, which are the polymorphic forms of pemetrexed diacid and DMSO of the well established composition that enable the preparation of the stable amorphous pemetrexed disodium, free of other crystalline forms inclusions, characterized by high pharmaceutical purity level above 99.7%, having the content of the single impurities below 0,1% and residual solvents below the level approved for active pharmaceutical ingredients.
  • DSC Differential scanning calorimetry
  • TGA Thermogravimetric measurements
  • DMSO dimethyl sulfoxide
  • ethanol residues using GC analysis were performed on the gas chromatograph equipped with a flame ionization detector.
  • GC analysis parameters for DMSO residue measurements column DB-WAX (30 m x 0,32 mm), column temperature 100°C (10°C/min) - 220°C (1 min), injector 240° C, carrier gas - nitrogen (50 kPa), split 20 : 1, detector: 260° C, hydrogen 40 mL/min, air 400 mL/min, injection ⁇ .
  • Pemetrexed diethyl ester -toluenesulfonate (922 g, 1.406 mol) was treated with 1.5 M NaOH aqueous solution (3688 mL), the mixture was stirred at ambient temperature for 2 h. Ethanol was added (4167 mL), pH of the reaction mixture was adjusted to about 3.0 adding 1.5 M HCl aqueous solution (3520 mL), the resulting mixture was heated at 70-75 °C. After cooling down the solution to ambient temperature, the solid was filtered off and washed with H 2 0-EtOH (1 :1, v/v) (2 x 1845 mL). The solid was dried in an air flow drier at 40-45°C. Pemetrexed diacid was obtained in 590 g yield (HPLC 99.10%). b) Crystallization of crude pemetrexed diacid
  • the crude pemetrexed diacid (590 g, 1.38 mmol, HPLC 99.10%) was dissolved in DMSO (1263 mL) at 45-55°C. Ethanol (4794 mL) was added and the mixture was stirred for about 1 h. The solid was filtered off, washed with ethanol (3 x 2766 mL), air dried and dried in an air flow dryer at 40-45 °C to the constant mass (700 g, HPLC 99.48%).
  • Pemetrexed disodium salt (278 g, 0.590 mol) was dissolved in water (1800 mL).
  • the crude pemetrexed diacid (211 g, HPLC 99.19%) was dissolved in DMSO (443 mL) at 45-55°C for 1 h. Ethanol (1683 mL) was added and stirring was continued for about lh. The solid was filtered off, washed with ethanol (3x 323 mL) and dried in an air flow dryer at 40-45°C (230 g, HPLC 99.39%).
  • Methyl tert-butyl ether (MTBE) 500 mL was added, stirring was continued for 30 min, then the solid was filtered off and washed with MTBE-methanol (1 :1, v/v) (2 x 100 mL) and cold methanol (1 x 160 mL). The solid was dried to the constant mass in a rotary vacuum vaporator (water bath temperature 25-30°C/10-15 mbar) for 4 h. 34.7 g of pemetrexed disodium was obtained (99.48% HPLC, unidentified impurity RRT(1.03): 0.27%).
  • the amorphous pemetrexed disodium was macerated in cyclohexane (200 mL) at ambient temperature for 3 h. The solid was filtered off, washed with cyclohexane (75 mL) and dried to the constant mass in vacuum rotary vaporator (water bath temperature 25-40°C/10-15 mbar) for 4 h. 61.74 g of pemetrexed disodium was obtained (HPLC 99.71 %, GC: MeOH 108 ppm, EtOH 197 ppm, cyclohexane 35 ppm).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un procédé de préparation de pemetrexed disodique amorphe de haute pureté, caractérisée par la réaction de l'acide N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-L-glutamique avec un déficit molaire d'un composé générateur de cations sodium par rapport aux groupes carboxyle de l'acide libre, dans des conditions anhydres. De préférence, dans ce procédé, c'est la forme 1 ou la forme 2 cristalline pure de l'acide N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-L-glutamique contenant de 27 à 31 % de diméthylsulfoxyde qui est utilisée.
EP14732453.7A 2013-05-17 2014-05-16 Procédé pour la préparation de pemetrexed disodique amorphe de haute pureté et formes cristallines de l'acide n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-l-glutamique Withdrawn EP2997031A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL403942A PL403942A1 (pl) 2013-05-17 2013-05-17 Sposób wytwarzania soli disodowej pemetreksedu w postaci amorficznej o wysokiej czystości
PL408089A PL408089A1 (pl) 2014-04-30 2014-04-30 Sposób wytwarzania soli disodowej pemetreksedu w postaci amorficznej o wysokiej czystości i formy krystaliczne kwasu N-[4-(2-(-amino-4,7-dihydro-4-okso-3H-pirolo[2,3-d]pirymidyn-5-ylo)etylo]benzoilo]-L-glutaminowego
PCT/PL2014/000053 WO2014185797A1 (fr) 2013-05-17 2014-05-16 Procédé pour la préparation de pemetrexed disodique amorphe de haute pureté et formes cristallines de l'acide n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-l-glutamique

Publications (1)

Publication Number Publication Date
EP2997031A1 true EP2997031A1 (fr) 2016-03-23

Family

ID=50981830

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14732453.7A Withdrawn EP2997031A1 (fr) 2013-05-17 2014-05-16 Procédé pour la préparation de pemetrexed disodique amorphe de haute pureté et formes cristallines de l'acide n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-l-glutamique

Country Status (2)

Country Link
EP (1) EP2997031A1 (fr)
WO (1) WO2014185797A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107641124A (zh) * 2016-07-22 2018-01-30 上海创诺制药有限公司 一种培美曲塞二酸新晶型及其制备方法
CN114262332A (zh) * 2020-09-16 2022-04-01 齐鲁制药有限公司 培美曲塞二酸新晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
HUT70208A (en) 1992-09-25 1995-09-28 Lilly Co Eli Process for preparing 5-substituted pyrrolo[2,3-d]-pyrimidines
WO2001014379A2 (fr) 1999-08-23 2001-03-01 Eli Lilly And Company Nouvelle forme cristalline de disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l- sel d'acide glutamique et procedes de preparation
WO2008021405A1 (fr) 2006-08-14 2008-02-21 Sicor Inc. Formes cristallines de diacide de pemetrexed et leurs procédés de préparation
EP1934226A2 (fr) * 2006-08-14 2008-06-25 Sicor, Inc. Diacide de pemetrexed de haute pureté et ses procédés de préparation
KR101083230B1 (ko) 2006-08-14 2011-11-11 시코르, 인크. 페메트렉세드 이산의 동결 건조된 약학적 허용염의 제조 방법
EP2129674A2 (fr) 2007-04-03 2009-12-09 Dr. Reddy's Laboratories Ltd. Formes solides de pemetrexed
EP2072518A1 (fr) 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Forme amorphe stable de Pemextred disodium
EP2334685A4 (fr) 2008-09-08 2011-10-26 Reddys Lab Ltd Dr Disodium de pemetrexed amorphe
CN101684121B (zh) 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014185797A1 *

Also Published As

Publication number Publication date
WO2014185797A1 (fr) 2014-11-20

Similar Documents

Publication Publication Date Title
AU2017284702B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
KR20080050594A (ko) 페메트렉세드 이산의 결정형 및 이의 제조 방법
US11332467B2 (en) Solid state forms of palbociclib dimesylate
KR20190133724A (ko) (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법
AU2015330554A1 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CN111777595A (zh) 一种环己烷甲酰胺类化合物的新晶型及其制备方法
JP2008543975A (ja) 高度に純粋なペメトレキセド二酸およびその調製方法
AU2021277593A1 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
AU2018234306B2 (en) Salts of antiviral phosphonate analogues and process for preparation thereof
CN108884099B (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN116528864A (zh) 杂芳基甲酰胺化合物
US20080262025A1 (en) Processes for the Preparation of Zolpidem and its Hemitartrate
WO2018041260A1 (fr) Inhibiteur de protéine de reconnaissance de bromodomaine, son procédé de préparation et son utilisation
EP2997031A1 (fr) Procédé pour la préparation de pemetrexed disodique amorphe de haute pureté et formes cristallines de l'acide n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-l-glutamique
CN115160186B (zh) 氨基甲酸苯酯晶型及其制备方法
WO2013132314A1 (fr) Phosphate de type ténofovir, procédés de préparation et composition pharmaceutique de celui-ci
US11111250B2 (en) Polymorphs of Ribociclib mono succinate
CN118076614A (zh) 一种egfr抑制剂的多晶型
US20220162185A1 (en) Crystalline and amorphous forms of n-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
JP2023544775A (ja) ７－クロロ－６－フルオロ－１－（２－イソプロピル－４－メチルピリジン－３－イル）ピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオンのアトロプ異性体をラセミ化及び単離するためのプロセス
CN109516975B (zh) 取代嘧啶类pi3k抑制剂的可药用盐及其制备方法
EP3604284B1 (fr) Forme cristalline d du sel de monoéthanolamine d'eltrombopag
WO2020224208A1 (fr) Forme cristalline d'un dérivé de pyridone, procédé de préparation correspondant et utilisation associée
TW201209058A (en) A novel process for the synthesis of pemetrexed disodium salt
CN109516976B (zh) 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160817